On November 6, 2023, Alpine Immune Sciences, Inc., a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and pre-funded warrants to purchase up to 3,200,000 shares of its common stock, pursuant to its existing shelf registration statement. Wilson Sonsini Goodrich & Rosati advised Alpine Immune Sciences on the transaction.

The shares of common stock are being offered at a public offering price of $12.50 per share and the pre-funded warrants are being offered at a price of $12.499 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.001 exercise price per share of each pre-funded warrant. The gross proceeds from the offering are expected to be approximately $150 million before deducting underwriting discounts and commissions and other offering expenses payable by Alpine. In addition, Alpine has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 1,800,000 shares of common stock at the public offering price, less the underwriting discounts and commissions.

The offering closed on November 9, 2023.

The Wilson Sonsini team that advised Alpine Immune Sciences on the transaction included:

Corporate
Patrick Schultheis
Michael Nordtvedt
Bryan King
James Babikian
Aletha Tarn
Katie Obermiller
Nicole Marshall

Specialists
Eva Yin
Matt Staples
Lori Westin
Myra Sutanto Shen
Han Shen

For more information, please see Alpine Immune Sciences’ press release.